To the top

Page Manager: Webmaster
Last update: 9/11/2012 3:13 PM

Tell a friend about this page
Print version

Lamivudine resistance of … - University of Gothenburg, Sweden Till startsida
To content Read more about how we use cookies on

Lamivudine resistance of hepatitis B virus masked by coemergence of mutations in probe region of the COBAS AMPLICOR assay.

Review article
Authors Magnus Lindh
Charles Hannoun
Sebastian Malmström
Johan Lindberg
Gunnar Norkrans
Published in Journal of clinical microbiology
Volume 44
Issue 7
Pages 2587-9
ISSN 0095-1137
Publication year 2006
Published at Institute of Biomedicine, Department of Infectious Medicine
Pages 2587-9
Language en
Keywords Antiviral Agents, pharmacology, Base Sequence, DNA Probes, DNA, Viral, chemistry, genetics, Drug Resistance, Viral, genetics, False Negative Reactions, Hepatitis B virus, drug effects, genetics, Hepatitis B, Chronic, drug therapy, virology, Humans, Lamivudine, pharmacology, Male, Middle Aged, Molecular Sequence Data, Mutation, Reagent Kits, Diagnostic, Sequence Analysis, DNA, Viral Load
Subject categories Medical and Health Sciences


The COBAS AMPLICOR hepatitis B virus assay targets a conserved region of the genome and is widely used to monitor treatment of hepatitis B in order to identify emerging resistance. However, the assay failed to recognize increasing viremia levels when YMDD mutations were paralleled by mutations in the segment targeted by the COBAS AMPLICOR probe.

Page Manager: Webmaster|Last update: 9/11/2012

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?